Girard Partners’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $1.59M | Buy |
1,754
+1
| +0.1% | +$800 | 0.15% | 112 |
|
|
2024
Q1 | $1.36M | Sell |
1,753
-120
| -6% | -$85.4K | 0.13% | 125 |
|
|
2023
Q4 | $1.09M | Sell |
1,873
-68
| -4% | -$39.7K | 0.11% | 145 |
|
|
2023
Q3 | $1.04M | Sell |
1,941
-85
| -4% | -$43.8K | 0.12% | 135 |
|
|
2023
Q2 | $950K | Sell |
2,026
-170
| -8% | -$71.3K | 0.1% | 141 |
|
|
2023
Q1 | $754K | Buy |
2,196
+90
| +4% | +$30.4K | 0.08% | 148 |
|
|
2022
Q4 | $770K | Buy |
2,106
+599
| +40% | +$212K | 0.09% | 162 |
|
|
2022
Q3 | $487K | Sell |
1,507
-48
| -3% | -$15.2K | 0.06% | 165 |
|
|
2022
Q2 | $504K | Buy |
1,555
+7
| +0.5% | +$2.1K | 0.06% | 160 |
|
|
2022
Q1 | $443K | Buy |
1,548
+25
| +2% | +$6.43K | 0.05% | 174 |
|
|
2021
Q4 | $420K | Sell |
1,523
-100
| -6% | -$25.4K | 0.05% | 183 |
|
|
2021
Q3 | $374K | Sell |
1,623
-222
| -12% | -$54.8K | 0.05% | 179 |
|
|
2021
Q2 | $423K | Sell |
1,845
-94
| -5% | -$18.9K | 0.05% | 175 |
|
|
2021
Q1 | $362K | Sell |
1,939
-19
| -1% | -$3.72K | 0.05% | 176 |
|
|
2020
Q4 | $330K | Sell |
1,958
-922
| -32% | -$138K | 0.05% | 178 |
|
|
2020
Q3 | $426K | Sell |
2,880
-438
| -13% | -$67.8K | 0.07% | 156 |
|
|
2020
Q2 | $544K | Sell |
3,318
-812
| -20% | -$125K | 0.1% | 131 |
|
|
2020
Q1 | $572K | Buy |
4,130
+24
| +0.6% | +$3.3K | 0.11% | 129 |
|
|
2019
Q4 | $539K | Buy |
4,106
+101
| +3% | +$11.7K | 0.09% | 146 |
|
|
2019
Q3 | $447K | Sell |
4,005
-967
| -19% | -$108K | 0.08% | 149 |
|
|
2019
Q2 | $550K | Buy |
4,972
+24
| +0.5% | +$2.83K | 0.1% | 146 |
|
|
2019
Q1 | $642K | Buy |
4,948
+477
| +11% | +$58K | 0.12% | 136 |
|
|
2018
Q4 | $517K | Sell |
4,471
-862
| -16% | -$96.3K | 0.11% | 150 |
|
|
2018
Q3 | $572K | Sell |
5,333
-2,260
| -30% | -$226K | 0.1% | 148 |
|
|
2018
Q2 | $648K | Buy |
7,593
+446
| +6% | +$36.6K | 0.12% | 149 |
|
|
2018
Q1 | $553K | Sell |
7,147
-967
| -12% | -$77.8K | 0.13% | 143 |
|
|
2017
Q4 | $685K | Buy |
8,114
+1,297
| +19% | +$110K | 0.13% | 148 |
|
|
2017
Q3 | $583K | Sell |
6,817
-216
| -3% | -$17.7K | 0.12% | 143 |
|
|
2017
Q2 | $579K | Sell |
7,033
-310
| -4% | -$25.3K | 0.13% | 144 |
|
|
2017
Q1 | $618K | Buy |
7,343
+1,157
| +19% | +$92.7K | 0.15% | 136 |
|
|
2016
Q4 | $455K | Sell |
6,186
-3,614
| -37% | -$269K | 0.13% | 150 |
|
|
2016
Q3 | $787K | Sell |
9,800
-183
| -2% | -$14.6K | 0.26% | 104 |
|
|
2016
Q2 | $786K | Buy |
9,983
+228
| +2% | +$17.2K | 0.3% | 90 |
|
|
2016
Q1 | $702K | Sell |
9,755
-2,847
| -23% | -$215K | 0.31% | 91 |
|
|
2015
Q4 | $1.06M | Sell |
12,602
-505
| -4% | -$41.9K | 0.51% | 65 |
|
|
2015
Q3 | $1.1M | Buy |
13,107
+438
| +3% | +$37K | 0.62% | 56 |
|
|
2015
Q2 | $1.06M | Sell |
12,669
-367
| -3% | -$28K | 0.59% | 60 |
|
|
2015
Q1 | $947K | Sell |
13,036
-588
| -4% | -$41.9K | 0.56% | 62 |
|
|
2014
Q4 | $940K | Buy |
13,624
+88
| +0.7% | +$5.94K | 0.59% | 58 |
|
|
2014
Q3 | $878K | Sell |
13,536
-1,127
| -8% | -$71.4K | 0.59% | 56 |
|
|
2014
Q2 | $912K | Buy |
14,663
+2,622
| +22% | +$156K | 0.63% | 53 |
|
|
2014
Q1 | $709K | Buy |
12,041
+2,404
| +25% | +$134K | 0.5% | 63 |
|
|
2013
Q4 | $491K | Buy |
+9,637
| New | +$483K | 0.39% | 69 |
|
Other funds holding LLY
Girard Partners's LLY Position: Q2 2024 in Review
Girard Partners increased its Eli Lilly (LLY) stake by 0.06% in Q2 2024, buying an estimated $800 and bringing the position to 1,754 shares worth $1.59M. The position accounts for 0.15% of the portfolio, ranked #112.
Girard Partners first reported a position in LLY in Q4 2013 and has held it in 43 quarters since. 3,564 funds tracked by Wall St. Rank hold LLY as of Q2 2024.
- Girard Partners held 1,754 shares of Eli Lilly worth $1.59M as of Q2 2024.
- Girard Partners bought 1 Eli Lilly share in Q2 2024, an estimated $800.
- Eli Lilly made up 0.15% of Girard Partners's portfolio in Q2 2024, its #112 holding.
- Girard Partners first reported a position in Eli Lilly in Q4 2013 and has held it in 43 quarters since.
- 3,564 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2024.
Based on Girard Partners's 13F filing for Q2 2024, filed 12 Aug 2024.